SOUTH SAN FRANCISCO, CA – [Date of publication, e.g., October 26, 2026] – Encoded Therapeutics, a clinical-stage biotechnology company pioneering precision gene therapies, has announced the successful close of a monumental $275 million Series F financing round. This substantial investment is earmarked to propel the company’s lead candidate, ETX101, into a pivotal trial for paediatric patients suffering from SCN1A+ Dravet syndrome, a severe and life-altering form of epilepsy. Beyond this critical advancement, the funding will also bolster Encoded’s broader pipeline, including the progression of a new gene therapy candidate, ETX301, and the scaling of its internal Good Manufacturing Practice (GMP) capabilities.
n
The financing round, co-led by prominent venture capital firm GV and another undisclosed healthcare fund, attracted significant participation from a robust syndicate of institutional investors. Notable participants include ARCH Venture Partners, Janus Henderson Investors, and Farallon Capital Management, among others, underscoring strong investor confidence in Encoded’s innovative gene therapy platform and its potential to address profound unmet medical needs. This capital infusion positions Encoded Therapeutics at the forefront of genetic medicine, promising a new era of treatment for patients battling devastating neurological disorders.
n
A Landmark Investment in Genetic Medicine
n
The $275 million Series F represents a pivotal moment for Encoded Therapeutics and the wider gene therapy landscape. In an increasingly competitive and capital-intensive biotech sector, securing such a substantial investment highlights the compelling clinical data generated thus far by ETX101 and the strategic vision of Encoded’s leadership. The funds will be strategically deployed to advance ETX101 through its crucial pivotal trial, a final stage before potential regulatory submission and market access.
n
Dravet syndrome, a rare and severe form of epilepsy, profoundly impacts the lives of affected children and their families. Current treatments largely focus on symptom management, often with limited efficacy and significant side effects. Encoded’s ETX101 offers the potential for a disease-modifying therapy, addressing the genetic root cause of the condition, a paradigm shift in how Dravet syndrome could be managed. This investment not only validates Encoded’s scientific approach but also signals a collective hope from the investment community for a transformative therapeutic breakthrough.
n
Driving Forward a Pivotal Trial for ETX101
n
The primary allocation of the Series F proceeds will be directed towards initiating a pivotal trial for ETX101. This trial will specifically target infants and young children diagnosed with SCN1A+ Dravet syndrome, the most common genetic subtype of the disorder. In parallel, Encoded plans to launch an expansion study to assess ETX101’s efficacy and safety in a broader age group, encompassing children and adolescents up to 18 years of age. This dual approach aims to gather comprehensive data across different developmental stages, paving the way for a wide-ranging indication if successful.
n
The decision to move directly into a pivotal trial underscores the compelling evidence generated in earlier studies. Pivotal trials are typically large, well-controlled studies designed to provide definitive evidence of a therapy’s safety and efficacy, often serving as the basis for regulatory approval. For a rare paediatric disease like Dravet syndrome, accelerating this process is paramount, as every year without an effective treatment represents lost developmental opportunities and continued suffering for young patients. Encoded’s commitment to swiftly bringing ETX101 to market reflects the urgent unmet need within the Dravet syndrome community.
n
The Promise of ETX101: Addressing the Root Cause
n
ETX101 stands out as a potential one-time gene therapy designed to address the fundamental genetic defect underlying Dravet syndrome. More than 90% of Dravet syndrome cases are caused by a loss-of-function mutation in the SCN1A gene. This gene is crucial for the proper functioning of the Nav1.1 voltage-gated sodium channel, which plays a vital role in inhibitory interneurons in the brain. When the SCN1A gene is dysfunctional, these interneurons cannot effectively regulate neuronal excitability, leading to the characteristic severe and intractable seizures associated with the syndrome.
n
ETX101 aims to selectively increase the expression of a healthy, functional copy of the SCN1A gene. By delivering this therapeutic gene to the affected cells, the therapy intends to restore normal Nav1.1 channel function, thereby mitigating neuronal hyperexcitability and reducing seizure frequency. This approach represents a significant departure from conventional symptomatic treatments, which often target downstream effects rather than the underlying genetic cause. As a disease-modifying therapy, ETX101 holds the promise of not just controlling symptoms but potentially altering the natural course of Dravet syndrome, offering long-term benefits and improved neurological outcomes for patients.
n
Strong Clinical Foundations: The POLARIS Study
n
The confidence in ETX101’s potential is rooted in the encouraging results from the Phase I/II POLARIS study. This open-label, dose-escalation trial evaluated the safety and preliminary efficacy of a single administration of ETX101 in paediatric patients with SCN1A+ Dravet syndrome. The interim data, recently presented at the European Epilepsy Congress, provided a compelling glimpse into the therapy’s transformative potential.
n
Patients who completed a year of follow-ups after receiving a single administration of ETX101 at the third dose level experienced a remarkable reduction in monthly seizure frequency, by up to 79%. This statistically and clinically significant reduction in seizures is a critical endpoint for Dravet syndrome therapies, as frequent and prolonged seizures are a hallmark of the disease and contribute to significant morbidity. Beyond seizure control, the POLARIS data also demonstrated "encouraging developmental gains." While specific details on these gains were not fully disclosed, they typically encompass improvements in cognitive function, motor skills, communication abilities, and adaptive behaviors – areas profoundly impacted by Dravet syndrome. These developmental improvements are particularly significant, suggesting that ETX101 may not only reduce seizure burden but also positively influence neurodevelopmental trajectories, offering a more holistic benefit to young patients. The positive safety profile observed in the study further supports the progression of ETX101 into pivotal trials.
n
Leadership’s Vision and Official Responses
n
Kartik Ramamoorthi, CEO of Encoded Therapeutics, articulated the company’s enthusiasm and strategic direction following the successful financing round. "The interim Phase I/II POLARIS data we recently shared at the European Epilepsy Congress demonstrate substantial and sustained seizure frequency reductions alongside encouraging developmental gains. This progress strengthens our conviction in ETX101 and the potential of our approach to meaningfully alter the course of Dravet syndrome," Ramamoorthi stated. His remarks underscore the scientific rigor and clinical promise that has driven Encoded’s trajectory.
n
Ramamoorthi further emphasized the strategic implications of the Series F funding, stating, "With pivotal development underway, this financing gives us the resources to advance ETX101 toward registration while continuing to build the capabilities and pipeline that will define Encoded’s next stage." This statement highlights a dual objective: the immediate focus on bringing ETX101 to market and the broader long-term vision of establishing Encoded as a leader in precision genetic therapies. The CEO’s vision points to a future where Encoded not only addresses Dravet syndrome but also leverages its platform to tackle other challenging neurological conditions, reinforcing the company’s commitment to innovation and patient impact. The financing is a testament to the belief in both the immediate potential of ETX101 and the enduring value of Encoded’s scientific foundation.
n
The Competitive Landscape: A Race for a Cure
n
Encoded Therapeutics is racing to market the first disease-modifying therapy for Dravet syndrome, a goal shared by other innovative biopharmaceutical companies. The competitive landscape underscores the significant unmet medical need and the intense scientific effort being directed towards this devastating condition.
n
A notable competitor is the collaboration between Biogen and Stoke Therapeutics, which recently made headlines with a deal worth up to $550 million for certain regional rights to Stoke Therapeutics’ zorevunersen. This antisense oligonucleotide (ASO) therapy, unlike Encoded’s gene therapy, instructs cells to make a healthy copy of the SCN1A gene in Dravet syndrome patients. While both approaches aim to restore SCN1A function, their mechanisms of action differ: ETX101 delivers a functional gene, whereas zorevunersen modulates RNA processing to increase endogenous healthy protein production. Biogen and Stoke are currently conducting the Phase III EMPEROR study for zorevunersen, with a readout from this pivotal trial anticipated later this year. The success of either or both therapies would represent a monumental shift in the treatment paradigm for Dravet syndrome, offering hope where little existed before. The simultaneous advancement of these distinct therapeutic modalities highlights the scientific community’s multifaceted attack on rare genetic disorders.
n
Understanding Dravet Syndrome: A Devastating Rare Disease
n
Dravet syndrome is a catastrophic, lifelong form of epilepsy that begins in infancy, typically within the first year of life. Characterized by frequent, prolonged, and drug-resistant seizures, it often progresses from febrile seizures to various seizure types, including generalized tonic-clonic, myoclonic, and atypical absence seizures. These seizures are often triggered by fever, hot water, excitement, or flashing lights, making everyday activities a constant challenge for patients and their caregivers.
n
Beyond the severe seizure burden, Dravet syndrome is associated with significant developmental delays and a range of comorbidities. Children often experience intellectual disability, speech and motor impairments, ataxia (lack of muscle coordination), behavioral problems (including features of autism spectrum disorder and attention deficit hyperactivity disorder), and sleep disturbances. The progressive nature of these developmental and neurological deficits severely impacts the quality of life for affected individuals, requiring intensive and continuous care.
n
While precise epidemiological data for Dravet syndrome patients in the US can be challenging to ascertain, it is estimated to affect approximately one in every 16,000 to 21,000 live births. According to the National Organization for Rare Disorders (NORD), it accounts for roughly 0.17% of all epilepsy cases, classifying it as an ultra-rare disease. The high prevalence of SCN1A gene mutations (over 90% of cases) makes it a prime target for gene-specific therapies. Current management involves a polytherapy regimen of multiple anti-epileptic drugs, often combined with ketogenic diets or vagus nerve stimulation, but these approaches are largely symptomatic and often fail to achieve adequate seizure control or address the broader neurodevelopmental challenges. The profound unmet medical need for truly disease-modifying therapies in Dravet syndrome cannot be overstated.
n
Expanding Horizons: Beyond Dravet Syndrome
n
The $275 million Series F tranche extends its benefits beyond the immediate advancement of ETX101. A significant portion of the funding is also allocated to support the commercial scale-up of Encoded’s internal GMP manufacturing capabilities. For gene therapy companies, having robust in-house manufacturing is a critical strategic advantage. It ensures stringent quality control, streamlines the supply chain, reduces reliance on external contract manufacturing organizations (CMOs), and ultimately can lead to more cost-effective and efficient production of complex biological therapies. This investment signifies Encoded’s commitment to becoming a fully integrated biopharmaceutical company, capable of not only developing but also reliably producing its cutting-edge therapies.
n
Furthermore, the financing will accelerate the advancement of Encoded’s broader pipeline. A notable beneficiary is ETX301, another promising asset slated for an Investigational New Drug (IND) submission in 2027. ETX301 is being developed for the treatment of post-amputation neuroma pain, a chronic and often debilitating condition that arises after limb amputation. Neuromas are bundles of nerve tissue that can form at the site of a severed nerve, leading to persistent, severe localized pain that is often resistant to conventional analgesics. By targeting this specific and challenging pain indication with a gene therapy approach, Encoded aims to provide long-lasting relief to patients suffering from this often-overlooked and underserved condition. This expansion demonstrates Encoded’s platform versatility and its potential to address a wider range of neurological and pain disorders beyond rare epilepsies.
n
Chronology of Encoded Therapeutics’ Milestones
n
Encoded Therapeutics has steadily built its foundation, culminating in this significant Series F funding round. While specific dates for all past events are not detailed in the original article, a general chronology can be inferred from the progression of its lead asset and corporate strategy:
n
- Early-to-Mid 2010s: Foundational research and preclinical development of its gene therapy platform, likely focusing on identifying key genetic targets and developing robust viral vector delivery systems.
- Late 2010s: Initial seed and Series A funding rounds to support preclinical studies and early team expansion. Identification of SCN1A as a primary target for Dravet syndrome.
- Early 2020s: Continued preclinical development of ETX101, leading to the filing of an Investigational New Drug (IND) application with regulatory authorities.
- Mid-2020s: Initiation of the Phase I/II POLARIS study for ETX101 in patients with SCN1A+ Dravet syndrome. This marked the company’s entry into clinical development.
- Recent Past: Presentation of positive interim Phase I/II POLARIS data at major scientific conferences, demonstrating significant seizure reduction and developmental gains. This data proved crucial in attracting the current Series F investment.
- Present (Late 2026): Successful completion of the $275 million Series F financing round. Announcement of plans to initiate a pivotal trial for ETX101 and an expansion study for adolescents. Allocation of funds to internal GMP manufacturing scale-up and advancement of ETX301 towards IND submission.
This progression highlights a methodical and data-driven approach, moving from foundational science to promising clinical results, which has successfully attracted substantial investor confidence.
The Broader Impact of Gene Therapy on Rare Diseases
Encoded Therapeutics’ journey with ETX101 is emblematic of a broader trend in pharmaceutical innovation: the transformative potential of gene therapy for rare genetic diseases. For conditions like Dravet syndrome, which are caused by a single gene defect, gene therapy offers the tantalizing prospect of a one-time, curative, or at least disease-modifying, treatment. This approach bypasses the limitations of symptomatic management, offering the potential to correct the underlying biological pathology.
However, the field of gene therapy also faces significant challenges. These include the complexities of manufacturing high-quality viral vectors at commercial scale, the intricate regulatory pathways for novel biological products, and the high costs associated with developing and delivering these sophisticated treatments. Despite these hurdles, the success stories emerging from various indications, combined with the profound impact on patients’ lives, continue to attract substantial investment and scientific talent. Encoded’s significant financing underscores the ongoing belief that these challenges are surmountable and that gene therapies will play an increasingly central role in the future of medicine, particularly for rare and devastating diseases with high unmet needs.
Investor Confidence and Market Signals
The composition of Encoded’s Series F funding round, co-led by GV and supported by institutional giants like ARCH Venture Partners, Janus Henderson Investors, and Farallon Capital Management, sends a clear signal to the market. GV, the venture capital arm of Alphabet, is known for its strategic investments in life sciences, particularly in companies poised for disruptive innovation. ARCH Venture Partners is a prolific and highly respected investor in early-stage biotech, known for backing companies with groundbreaking science. The participation of these funds, alongside other major healthcare-focused investors, reflects a strong belief in Encoded’s scientific platform, its leadership team, and the commercial potential of ETX101.
This level of investment also indicates a robust and continued appetite for innovation in the gene therapy sector, even amidst broader economic uncertainties. Investors are increasingly sophisticated in evaluating the scientific merit and market potential of complex biological therapies. The successful closure of this round suggests that Encoded Therapeutics has met stringent due diligence criteria, demonstrating both compelling preclinical and clinical data and a clear strategic pathway to market. This influx of capital not only provides Encoded with the necessary resources but also enhances its credibility and attractiveness for future partnerships and talent acquisition.
The Path Ahead: Regulatory and Commercial Challenges
With pivotal development underway, Encoded Therapeutics now enters a critical phase that will determine ETX101’s journey to market. The design and execution of the pivotal trial will be paramount, requiring rigorous adherence to regulatory guidelines and robust data collection to demonstrate statistical significance and clinical meaningfulness. Engagement with regulatory bodies such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) will be continuous, ensuring the trial design aligns with approval requirements.
Beyond regulatory hurdles, Encoded will also need to navigate the complexities of commercialization. This includes developing a market access strategy, addressing pricing and reimbursement challenges for a high-value gene therapy, and building out a commercial infrastructure. For a rare disease like Dravet syndrome, patient identification and education will also be crucial. The investment in internal GMP manufacturing capabilities is a proactive step towards ensuring a reliable supply chain, a common challenge for gene therapies. The successful navigation of these interwoven scientific, regulatory, and commercial pathways will ultimately define ETX101’s ability to reach and transform the lives of Dravet syndrome patients worldwide.
A New Chapter for Dravet Syndrome Patients
The $275 million Series F financing round for Encoded Therapeutics marks a significant milestone, not just for the company, but more importantly, for the thousands of children and families living with Dravet syndrome. This substantial investment accelerates the development of ETX101, a promising gene therapy that has shown the potential to offer meaningful seizure reduction and developmental improvements by addressing the fundamental genetic cause of the disease.
As Encoded pushes forward with its pivotal trial and expands its pipeline, the biotech industry and patient communities will be closely watching. The hope is that ETX101, along with other emerging therapies, will usher in a new era of effective, disease-modifying treatments that can alleviate the profound suffering caused by Dravet syndrome and other severe neurological conditions. The commitment from leading investors underscores a collective belief in the power of genetic medicine to transform lives, opening a new chapter of hope for those who have long awaited a breakthrough.
